GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Cyclically Adjusted PB Ratio

ImmuCell (ImmuCell) Cyclically Adjusted PB Ratio : 1.08 (As of May. 01, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Cyclically Adjusted PB Ratio?

As of today (2024-05-01), ImmuCell's current share price is $4.91. ImmuCell's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $4.55. ImmuCell's Cyclically Adjusted PB Ratio for today is 1.08.

The historical rank and industry rank for ImmuCell's Cyclically Adjusted PB Ratio or its related term are showing as below:

ICCC' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.95   Med: 1.72   Max: 3.18
Current: 1.12

During the past years, ImmuCell's highest Cyclically Adjusted PB Ratio was 3.18. The lowest was 0.95. And the median was 1.72.

ICCC's Cyclically Adjusted PB Ratio is ranked better than
62.25% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs ICCC: 1.12

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ImmuCell's adjusted book value per share data for the three months ended in Dec. 2023 was $3.225. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.55 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


ImmuCell Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ImmuCell's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Cyclically Adjusted PB Ratio Chart

ImmuCell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.36 1.54 1.92 1.36 1.12

ImmuCell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.14 1.09 1.16 1.12

Competitive Comparison of ImmuCell's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, ImmuCell's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ImmuCell's Cyclically Adjusted PB Ratio falls into.



ImmuCell Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ImmuCell's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.91/4.55
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, ImmuCell's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.225/129.4194*129.4194
=3.225

Current CPI (Dec. 2023) = 129.4194.

ImmuCell Quarterly Data

Book Value per Share CPI Adj_Book
201403 3.103 99.695 4.028
201406 3.007 100.560 3.870
201409 3.014 100.428 3.884
201412 3.058 99.070 3.995
201503 3.218 99.621 4.181
201506 3.257 100.684 4.187
201509 3.371 100.392 4.346
201512 3.474 99.792 4.505
201603 3.906 100.470 5.031
201606 3.901 101.688 4.965
201609 3.918 101.861 4.978
201612 4.069 101.863 5.170
201703 4.201 102.862 5.286
201706 4.166 103.349 5.217
201709 4.148 104.136 5.155
201712 4.309 104.011 5.362
201803 4.287 105.290 5.269
201806 4.160 106.317 5.064
201809 4.134 106.507 5.023
201812 3.904 105.998 4.767
201903 4.196 107.251 5.063
201906 4.112 108.070 4.924
201909 4.049 108.329 4.837
201912 4.019 108.420 4.797
202003 4.019 108.902 4.776
202006 3.921 108.767 4.665
202009 3.885 109.815 4.579
202012 3.916 109.897 4.612
202103 3.860 111.754 4.470
202106 4.168 114.631 4.706
202109 4.193 115.734 4.689
202112 4.208 117.630 4.630
202203 4.310 121.301 4.598
202206 4.231 125.017 4.380
202209 4.129 125.227 4.267
202212 3.922 125.222 4.053
202303 3.635 127.348 3.694
202306 3.467 128.729 3.486
202309 3.358 129.860 3.347
202312 3.225 129.419 3.225

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ImmuCell  (NAS:ICCC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ImmuCell Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ImmuCell's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuCell (ImmuCell) Business Description

Industry
Traded in Other Exchanges
Address
56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
Executives
Bryan K. Gathagan director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen director C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin other: See Explanation of Responses C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin other: See Explanation of Responses 310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb director, officer: Vice President and CSO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams officer: Vice Pres. of Mfg Operations C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild director, 10 percent owner C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham director, officer: President and CEO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde other: Director of Sales and Marketin 56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce director 56 EVERGREEN DRIVE, PORTLAND ME 04103